Promoted Content Promoted Content

X

Find Clinical Drug Development Pipelines & Deals | PipelineProspector

Loading...

All Data

Filters Filter
×
FILTER:
filter News Type
    filter Company
      filter Product Type
        filter Deal Size
          filter Upfront Payment

            Active Filter(s):

            Product Type

            Companies

            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Lead Product(s): Landiolol Hydrochloride

            Therapeutic Area: Cardiology/Vascular Diseases Product Name: LDLL600

            Highest Development Status: Phase III Product Type: Small molecule

            Partner/Sponsor/Collaborator: Eagle Pharmaceuticals

            Deal Size: Undisclosed Upfront Cash: $5.0 million

            Deal Type: Licensing Agreement August 09, 2021

            Details:

            The Company will support the submission of a new drug application to the U.S. FDA seeking approval for Landiolol for the short-term reduction of ventricular rate in patients with supraventricular tachycardia, including atrial fibrillation and atrial flutter.